Search the Newsreel

Why Alto Neuroscience (ANRO) Is Up 13.5% After Expanding ALTO-207 Phase 3 And Securing New Funding

Alto Neuroscience (ANRO) saw a 13.5% stock increase after expanding its ALTO-207 Phase 3 trial for treatment-resistant depression and securing approximately $100 million in new funding. Despite ongoing net losses, the company aims to validate its data-driven approach, with short-term focus on the expanded …

Trading the Move, Not the Narrative: (INBX) Edition

This article provides an in-depth analysis of Inhibrx Biosciences Inc (INBX), highlighting strong sentiment across all time horizons and an exceptional 100.9:1 risk-reward setup. It outlines three distinct AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis to guide trading decisions.

Regency Centers’ Higher Payouts and Raised Guidance Might Change The Case For Investing In REG

Regency Centers recently declared higher quarterly cash dividends and raised its full-year Nareit FFO and same-property NOI guidance, signaling confidence in its operating performance and a continued focus on distributing cash to shareholders. This move reinforces the REIT's income-focused thesis, emphasizing the durability of …

Ck Life Sciences Int'l., (Holdings) - LSI - Stock Price & News

Why Tencent Music Stock Sank This Week

Tencent Music's stock experienced a 7.2% decline this week despite reporting better-than-expected Q2 sales and earnings. Investors were more concerned with increasing operating expenses and a decline in its social entertainment services unit. While music-related services grew, the overall market sentiment for Chinese tech …

Regency Centers (REG) Q2 2026 Earnings Call Transcript

Industry Analysts Just Made A Huge Upgrade To Their Xencor, Inc. (NASDAQ:XNCR) Revenue Forecasts

Industry analysts have significantly upgraded their revenue forecasts for Xencor, Inc. (NASDAQ:XNCR) for 2026, with the consensus estimate now at US$144 million, a 37% increase from the previous year's sales. This revised outlook suggests a much more bullish perspective on the company's prospects, forecasting …

How Investors Are Reacting To Forte Biosciences (FBRX) Widening Losses But Slightly Improved Per-Share Results

Forte Biosciences reported increased net losses in Q2 and H1 2026 but saw a slight improvement in basic loss per share due to share count adjustments. The company's investment narrative is now heavily tied to its pending sale to argenx and the cash tender …

Uravi Defence and Technology Publishes Q1 FY27 Unaudited Results, Highlights Governance Focus

CSTL (CSTL) insider and family trusts detail planned and recent stock sales

A recent SEC Form 144 filing indicates a planned sale of 25,792 shares of CSTL common stock, valued at $763,959.04, by an insider and related family trusts, to be executed around August 14, 2026, through Goldman Sachs & Co. LLC. The filing also details …

Walleye Capital LLC Acquires Shares of 347,898 Tyra Biosciences, Inc. $TYRA

Walleye Capital LLC has acquired a new stake of 347,898 shares in Tyra Biosciences, Inc. (NASDAQ:TYRA), valued at approximately $11.1 million, bringing institutional ownership in the company to 84.14%. Despite the stock opening at $25.29, well below its 52-week high, analysts maintain a "Moderate …

Uravi Defence Q1 Results: Consolidated Net Profit Up 156% YoY

Walleye Capital LLC Buys Shares of 386,183 IDEAYA Biosciences, Inc. $IDYA

Walleye Capital LLC has acquired 386,183 shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA) during the second quarter, a new stake valued at approximately $14.4 million. This purchase represents 0.44% of IDEAYA Biosciences. Despite a reported quarterly loss of $1.22 per share, institutional ownership of the …

Forte Biosciences, Inc. (NASDAQ:FBRX) Given Average Recommendation of "Hold" by Brokerages

Forte Biosciences, Inc. (NASDAQ:FBRX) has received an average "Hold" rating from seven brokerages, with an average 12-month price target of $72.50, below its current $76.83 stock price. Recent analyst coverage has generally been negative, including downgrades from Wall Street Zen, Weiss Ratings, Barclays, and …

California State Teachers Retirement System Has $1.12 Million Stock Holdings in Kodiak Sciences Inc. $KOD

Assembly Biosciences, Inc. (NASDAQ:ASMB) Given Average Recommendation of "Moderate Buy" by Brokerages

Assembly Biosciences (NASDAQ:ASMB) has received an average "Moderate Buy" recommendation from brokerages, with five out of seven analysts rating the stock a buy. The average 12-month price target for ASMB is $44.00, significantly higher than its recent price of $32.95. The company also reported …

Gufic Biosciences Q1 Results: Net profit up 23% YoY to ₹80 crore

Everett Harris & Co. CA Acquires Shares of 80,341 Edwards Lifesciences Corporation $EW

Everett Harris & Co. CA has purchased 80,341 shares of Edwards Lifesciences Corporation (NYSE:EW) for approximately $7.27 million during the second quarter, marking a new stake in the company. This comes as other institutional investors have also adjusted their holdings in the medical research …

California State Teachers Retirement System Purchases 21,011 Shares of MBX Biosciences, Inc. $MBX

The California State Teachers Retirement System significantly increased its stake in MBX Biosciences by 1,197.9%, now holding 22,765 shares valued at $680,000. Other institutional investors also raised their positions in the company. Despite the company missing its Q2 earnings estimates, analysts maintain a "Moderate …

Dimensional Fund Advisors LP Invests $1.40 Million in MBX Biosciences, Inc. $MBX

Dimensional Fund Advisors LP has acquired a new stake worth $1.40 million in MBX Biosciences, Inc., representing 0.10% of the company. Other institutional investors have also increased their positions in MBX. Despite missing earnings estimates for the recent quarter, analysts generally maintain a "Moderate …

Silence Therapeutics closes $201.3M public offering By Investing.com

Silence Therapeutics plc (NASDAQ:SLN) has successfully closed an underwritten public offering, raising approximately $201.3 million. The offering included 14,907,407 American Depositary Shares at $13.50 per ADS, with underwriters fully exercising their option for additional shares. The gross proceeds will support the clinical-stage biotechnology company …

Abundance Wealth Counselors Grows Stake in Gilead Sciences, Inc. $GILD

Abundance Wealth Counselors significantly increased its stake in Gilead Sciences, Inc. by 93.7% in the second quarter, now holding 22,139 shares valued at $2.8 million. This comes as Gilead reported strong Q2 revenue growth of 10.6% to $7.8 billion, driven by its HIV franchise …

IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Receives Average Rating of "Moderate Buy" from Brokerages

IDEAYA Biosciences (NASDAQ:IDYA) has received an average rating of "Moderate Buy" from sixteen brokerages, with an average 12-month price target of $50.13, significantly above its current share price of $36.30. The company's recent quarterly results showed revenue exceeding expectations but missed on earnings per …

Handelsbanken Fonder AB Has $6.27 Million Position in Roivant Sciences Ltd. $ROIV

Handelsbanken Fonder AB significantly increased its stake in Roivant Sciences Ltd. during the second quarter, now holding 177,209 shares valued at $6.27 million. Institutional investors collectively own 64.76% of Roivant's stock, despite recent insider selling totaling approximately 2.06 million shares. Analysts maintain a "Moderate …

Science Applications International Corporation $SAIC Shares Acquired by Bank of America Corp DE

Bank of America Corp DE increased its stake in Science Applications International Corporation (SAIC) by 17.5% in the first quarter, acquiring an additional 56,720 shares, bringing its total to 380,538 shares valued at $36.1 million. The company's stock is primarily held by institutional investors, …

Nectar Lifesciences to Relocate Corporate Office Within Chandigarh Industrial Hub

T. Rowe Price Associates (TWST) discloses 3.63M-share Twist Bioscience position

T. Rowe Price Associates has reported a beneficial ownership of 3,634,470 shares of Twist Bioscience Corp. (TWST), representing a 5.8% stake in the company's common stock. The firm holds sole voting power over 3,520,536 shares and sole dispositive power over all 3,634,470 shares, as …

Independence Realty Trust (NYSE:IRT) Stock Rating Upgraded by Wall Street Zen

Wall Street Zen has upgraded Independence Realty Trust (NYSE:IRT) from a "strong sell" to a "sell" rating. Despite this, the broader analyst consensus remains a "Moderate Buy" with a target price of $19.56. The company recently missed quarterly EPS estimates but saw a 3.2% …

Precision Trading with Wave Life Sciences Ltd. (WVE) Risk Zones

This article from Stock Traders Daily provides a detailed analysis of Wave Life Sciences Ltd. (WVE), highlighting weak sentiment across all horizons supporting a short bias. It outlines institutional trading strategies, including long, breakout, and short positions, with specific entry zones, targets, and stop …

Gilead Sciences (NASDAQ:GILD) Upgraded to "Buy" at Wall Street Zen

Wall Street Zen has upgraded Gilead Sciences (NASDAQ:GILD) from a "Hold" to a "Buy" rating. This upgrade aligns with a "Moderate Buy" consensus among analysts, with an average price target of $158.04. The company recently reported strong quarterly results, exceeding revenue expectations, despite some …

Wall Street Zen Downgrades Kodiak Sciences (NASDAQ:KOD) to Sell

Wall Street Zen downgraded Kodiak Sciences (NASDAQ:KOD) from "hold" to "sell" on Saturday, despite the broader analyst consensus being a "Moderate Buy." The company's shares opened near their 52-week high at $41.35, but Kodiak Sciences reported a larger-than-expected quarterly loss of $1.05 per share. …

IDEAYA Biosciences (NASDAQ:IDYA) Rating Lowered to "Sell" at Wall Street Zen

Wall Street Zen downgraded IDEAYA Biosciences (NASDAQ:IDYA) from "hold" to "sell," despite the broader analyst consensus remaining a "Moderate Buy" with an average price target of $50.12. The company's shares opened at $36.30, and it recently reported a quarterly loss of $1.22 per share, …

TriSalus Life Sciences (NASDAQ:TLSI) Cut to "Sell" at Wall Street Zen

Kingfa Science & Technology (India) standalone net profit rises 101.58% in the June 2026 quarter

Achieve Life Sciences (NASDAQ:ACHV) Stock Rating Lowered by Wall Street Zen

Achieve Life Sciences (NASDAQ:ACHV) recently had its stock rating lowered from "hold" to "strong sell" by Wall Street Zen. Despite this downgrade, the company still holds an average "Buy" rating from other analysts with a consensus target price of $15.00. Achieve Life Sciences, a …

Gufic BioSciences consolidated net profit rises 70.70% in the June 2026 quarter